Analysed FIBROBIOLOGICS INC (FBLG:NASDAQ) News Sources
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
03-06-2026
yahoo.com
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
03-06-2026
yahoo.com
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
16-06-2026
yahoo.com
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
22-06-2026
yahoo.com
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
26-06-2026
yahoo.com
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
29-06-2026
yahoo.com
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
30-06-2026
yahoo.com
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
07-07-2026
yahoo.com
What is the current price of FIBROBIOLOGICS INC (FBLG:NASDAQ)?
The current price of FIBROBIOLOGICS INC (FBLG:NASDAQ) is $0.6271.
FIBROBIOLOGICS INC (FBLG:NASDAQ) absolute price change since previous trading day?
The absolute price change of FIBROBIOLOGICS INC (FBLG:NASDAQ) since the previous trading day is $-0.0849.
FIBROBIOLOGICS INC (FBLG:NASDAQ) percentage price change since previous trading day?
The percentage price change of FIBROBIOLOGICS INC (FBLG:NASDAQ) since the previous trading day is -11.9242%.
What is the most recent average sentiment score for FIBROBIOLOGICS INC (FBLG:NASDAQ)?
The most recent average sentiment score for FIBROBIOLOGICS INC (FBLG:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for FIBROBIOLOGICS INC (FBLG:NASDAQ)?
The most recent sentiment for FIBROBIOLOGICS INC (FBLG:NASDAQ) is .
SEC-8K** Filing Available For FIBROBIOLOGICS INC (FBLG:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.